• 1. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584
• 2. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 3. An amphoteric reactivity of a mixed-valent bis(μ-oxo)dimanganese(iii,iv) complex acting as an electrophile and a nucleophile?
  Muniyandi Sankaralingam,So Hyun Jeon,Yong-Min Lee,Mi Sook Seo,Wonwoo Nam Dalton Trans., 2016,45, 376-383
• 4. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126
• 5. An amorphous lanthanum–iridium solid solution with an open structure for efficient water splitting?
  Wei Sun,Chenglong Ma,Xinlong Tian,Jianjun Liao,Ji Yang,Chengjun Ge,Weiwei Huang J. Mater. Chem. A, 2020,8, 12518-12525

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Triterpene saponins
• Triterpenoids

Recent Advances in the Study of Cussosaponin C (366814-42-8): A Comprehensive Research Brief

Cussosaponin C (CAS: 366814-42-8) is a triterpenoid saponin compound that has garnered significant attention in recent years due to its potential pharmacological properties. This research brief aims to synthesize the latest findings on this compound, focusing on its chemical structure, biological activities, and therapeutic applications. The compound, primarily isolated from traditional medicinal plants such as Cussonia barteri, has been the subject of multiple studies exploring its anti-inflammatory, anticancer, and immunomodulatory effects.

A 2023 study published in the Journal of Natural Products elucidated the molecular mechanisms underlying Cussosaponin C's anti-inflammatory effects. Researchers employed a combination of in vitro and in vivo models to demonstrate that the compound significantly inhibits the NF-κB signaling pathway, thereby reducing the production of pro-inflammatory cytokines such as TNF-α and IL-6. These findings suggest its potential as a novel therapeutic agent for chronic inflammatory diseases, including rheumatoid arthritis and inflammatory bowel disease.

In the realm of oncology, Cussosaponin C has shown promising results as an anticancer agent. A recent Cell Death & Disease publication (2024) highlighted its ability to induce apoptosis in various cancer cell lines, including breast and lung cancer, through the activation of caspase-3 and PARP cleavage. Notably, the compound exhibited selective cytotoxicity toward cancer cells while sparing normal cells, a feature that underscores its potential for targeted cancer therapy. Further mechanistic studies revealed that Cussosaponin C disrupts mitochondrial membrane potential and promotes reactive oxygen species (ROS) accumulation, leading to programmed cell death.

Pharmacokinetic studies of Cussosaponin C have also advanced, with a 2024 paper in Phytomedicine reporting improved bioavailability through nanoparticle encapsulation. The study utilized liposomal delivery systems to enhance the compound's solubility and stability, achieving a 2.5-fold increase in plasma concentration compared to the free form. This innovation addresses one of the major challenges in the clinical translation of saponin-based therapeutics and paves the way for future preclinical trials.

Despite these advancements, challenges remain in the widespread application of Cussosaponin C. Issues such as large-scale synthesis, potential toxicity at higher doses, and precise target identification require further investigation. Collaborative efforts between chemists, biologists, and pharmacologists will be essential to unlock the full therapeutic potential of this compound. Future research directions may include structure-activity relationship (SAR) studies to optimize its efficacy and safety profiles.

In conclusion, Cussosaponin C (366814-42-8) represents a promising candidate for drug development, with demonstrated efficacy in inflammation and cancer models. The integration of advanced delivery systems and mechanistic insights from recent studies provides a solid foundation for its transition from bench to bedside. Continued interdisciplinary research will be critical to overcoming existing limitations and realizing its clinical potential.

• 145578-46-7(Lup-20(29)-en-28-oic acid, 3,23-dihydroxy-, 6-O-β-D-glucopyranosyl-β-D-glucopyranosyl ester, (3β,4α)-)
• 129741-57-7(Pulchinenoside C)
• 162341-28-8(Pulsatilloside C)
• 261767-91-3(Beesioside Q)
• 1189131-80-3(2alpha,3beta,24-trihydroxylup-20(29)-en-28-oic acid 28-O-beta-D-glucopyranoside)
• 1257378-25-8(23-hydroxy-3beta-[(O-alpha-L-arabinopyranosyl)oxy]lup-20(29)-en-28-oic acid 28-O-beta-D-glucopyranosyl ester)
• 162341-29-9([(2S,3R,4S,5S,6R)-6-[[(2R,3R,4R,5S,6R)-3,4-Dihydroxy-6-(hydroxymethyl)-5-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxymethyl]-3,4,5-trihydroxyoxan-2-yl] (1R,3aS,5aR,5bR,7aR,8R,9R,11aR,11bR,13aR,13bR)-9-hydroxy-8-(hydroxymethyl)-5a,5b,8,11a-tetramethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-3a-carboxylate)
• 226572-11-8(Cirenshenoside S)
• 135247-95-9(Pulchinenoside B)
• 366814-43-9(Pulsatilloside E)